Results 101 to 110 of about 10,795 (199)

Cyclosporin in atopic dermatitis: A multicentre placebo-controlled study [PDF]

, 1994
The efficacy of cyclosporin (Sandimmun®) given in a daily dose of 5 mg/kg for 6 weeks in severe atopic dermatitis was confirmed in this double-blind, placebo-controlled, short-term study.
Stenveld, H.J. (H.), Korstanje, M. (M.), Heule, F. (Freerk), Vloten, W.A. (Willem) van, Joost, Th. (Theo) van, Broek, M. (Marion) van den   +5 more
core   +1 more source

SARS‐CoV‐2 targets mitochondria, exacerbating COVID‐19 pneumonia

The Journal of Physiology, EarlyView.
Abstract figure legend Following entry into airway epithelial cells (AECs), SARS‐CoV‐2 releases its single‐stranded RNA into the cytoplasm, where it is translated into viral proteins. Several of these viral proteins localize to mitochondria and interact with key mitochondrial components.
Danchen Wu, Asish Dasgupta, Jaskaran Singh Hora, Kuang‐Hueih Chen, Arinjay Banerjee, Stephen L. Archer   +5 more
wiley   +1 more source

Better 10‐Year Cerebrovascular Outcome After Transplant Than on Standard‐Care in Sickle Cell Anemia: DREPAGREFFE Trial

American Journal of Hematology, Volume 101, Issue 8, Page 1799-1817, August 2026.
ABSTRACT Management of cerebral vasculopathy in sickle cell anemia (SCA) includes standard‐care, that is, chronic transfusion (CT) or hydroxyurea, and hematopoietic cell transplantation (HCT). DREPAGREFFE‐1 (December 2010/June 2013), a French multicenter trial, was the first prospective trial comparing standard‐care to match sibling donor (MSD)‐HCT in ...
Francoise Bernaudin, Suzanne Verlhac, Elisabeth Ducros‐Miralles, Cécile Arnaud, Isabelle Genty, Marie Petras, Catherine Paillard, Gonzalo De Luna, Benoit Meunier, Isabelle Thuret, Annie Kamdem, Corinne Pondarré, Giovanna Cannas, Christelle Chantalat‐Auger, Nadia Firah, Sophie Pertuisel, Laure Joseph, Florence Missud, Mariane de Montalembert, Corinne Guitton, Claire Pluchart, Valentine Brousse, Monique Elmaleh, Vincent Gajdos, Emmanuella Leveillé, Ekaterina Belozertseva, Mabel Gaba, Catherine Poirot, Virginie Barraud‐Lange, Philippe Chadebech, France Pirenne, Myriam Bernaudin, Bénédicte Neven, Pierre Frange, Marie Angoso, Karima Yakouben, Bénédicte Bruno, Nathalie Dhédin, Jean‐Hugues Dalle, Regis Peffault Delatour, Camille Jung   +40 more
wiley   +1 more source

Multiple Eruptive Sebaceous Hyperplasia Secondary to Cyclosporin in a Patient with Bone Marrow Transplantation

Dermatopathology, 2016
Many cutaneous complications have been described in patients treated with cyclosporin. Alterations of the pilosebaceous unit such as hypertrichosis are particularly frequent. However, the occurrence of sebaceous hyperplasia is exceptional.
Begonia Cortés, Gürkan Kaya
doaj   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

AlphaFold2‐Guided Cyclic Peptide Stabilizer Design to Target Protein–Protein Interactions

Proteins: Structure, Function, and Bioinformatics, Volume 94, Issue 7, Page 1356-1370, July 2026.
ABSTRACT The control and modulation of protein–protein interactions (PPIs) is of central importance for the majority of biological processes and most biomedical applications. Stabilization of PPIs, besides inhibition, is of growing pharmaceutical interest.
Niklas Halbwedl, Martin Zacharias
wiley   +1 more source

Cyclosporin A Treatment in Psoriasis: Monitoring by Neopterin Concentrations In Serum and Urine

Pteridines, 1993
Psoriasis is a hyperproliferative skin disorder in which immune mechanisms are thought to play a role. Recently, cyclosporin A has been found effective to treat psoriasis. However, mechanisms of action of cyclosporin A in patients are not well understood.
Sepp N., Benedikter S., Kofler H., Fritsch P., Wachter H., Fuchs D.   +5 more
doaj   +1 more source

Parkinson's Disease Cell Transplantation Therapy: A New Dawn With Pluripotent Stem Cell–Based Therapy

Journal of Neurochemistry, Volume 170, Issue 7, July 2026.
Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the midbrain. Cell transplantation, which aims to replace these lost neurons, has emerged as a promising approach. Early attempts using fetal ventral mesencephalic tissue showed proof‐of‐concept, with some patients achieving long‐term motor improvement. However,
Etsuro Nakanishi, Hodaka Yamakado, Nobukatsu Sawamoto, Jun Takahashi, Ryosuke Takahashi   +4 more
wiley   +1 more source

Combination Therapy Consisting of Low-dose Cyclosporin A, Low-dose Prednisolone and Enalapril in Children with Steroid-Sensitive Nephrotic Syndrome

, 2003
To evaluate the extent to which combined low-dose cyclosporin A (CsA), low - dose glucocorticoid and enalapril would permit decreasing 1) steroidal toxicity, 2) the frequency of relapse of nephrotic syndrome and 3) adverse effects due to CsA, in children
Fukuda, Masamichi
core   +1 more source